Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immunogenicity follow-up after pediatric TBE booster vaccination
2014-005105-20Phase 4
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Tick-borne encephalitis vaccine in tick-borne encephalitis (TBE), sponsored by Novartis. Primary endpoint: Percentage of subjects with neutralizing antibody titers at or above 10.
02
Drugs
Tick-borne encephalitis vaccine
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on 2014-005105-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005105-20.